Popular Arthritis Medicine Clinical Trial Shocks Experts
The FDA called for a clinical trial for the arthritis drug used by millions of people, Celebrex, to compare the risks to that of Vioxx, which was pulled in nearly a decade due to serious health correlations.
In 2004, Vioxx was withdrawn from the market after studies showed that daily use in patients may have caused a higher risk to having a heart attack, stroke and dying.
On Sunday, Dr. Steven Nissen of the Cleveland Clinic said his team’s 10-year research on Celebrex reassured that Celebrex had no cardiovascular problem links like Vioxx, despite their original hypothesis.
“Everybody was wrong, including me. In fact, the actual rate of heart disease events with Celebrex was a little bit lower than it was for these older drugs like ibuprofen and naproxen,” Nissen said, CBS News reported.
Nissen said there was approximately a 50 percent lower risk for patients to experience gastrointestional complications from Celebrax, which was created -along with Vioxx- to be sensitive on the digestive system compared to other pain relievers, CBS reported.
“It was better on gastrointestinal safety and that does give us choices. It gives physicians the opportunity to give a drug that is safe for the heart and possibly more safe for the stomach,” he said.